Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

NCT01497223 is registered in ClinicalTrials.gov with MethylGene Inc. as lead sponsor.

NCT NCT01497223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01497223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis
Lead sponsor
MethylGene Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
April 30, 2013
Enrollment
220 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

vulvovaginal candidiasis